De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring

Affiliations

• ¹ CIC 1436, Team Pharmacologie en Population, Cohortes et Biobanques, and.
• ² Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
• ³ Department of Internal Medicine, Adult Immune Cytopenias, Henry Mondor Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
• ⁴ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance, Henri Mondor University Hospital, Assistance Publique Hôpitaux de Paris, Paris-Est Créteil University, Créteil, France.
• ⁵ Centre of Pharmacovigilance, Rouen University Hospital, Rouen, France.
• ⁶ Regional Pharmacovigilance Center, Besançon University Hospital, Besançon, France.
• ⁷ Pharmacovigilance Center, Hospital University Pharmacotoxicology Department, Hospices Civils de Lyon, Lyon, France.
• ⁸ Department of Medical and Clinical Pharmacology, Centre of Pharmacovigilance and Pharmacoepidemiology, Faculty of Medicine, Toulouse University Hospital, Toulouse, France.
• ⁹ Department of Medical Pharmacology, Centre of Pharmacovigilance, Bordeaux University Hospital, Bordeaux, France; and.
• ¹⁰ INSERM, BPH, U1219, Team Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.